Evidence map›Paper›PMID 34922379›Full record

ArticleThe Journal of clinical endocrinology and metabolism2022

Long-Term Efficacy of Ethanol Ablation as Treatment of Metastatic Lymph Nodes From Papillary Thyroid Carcinoma.

Pål Stefan Frich, Eva Sigstad, Audun Elnæs Berstad, Kristin Holgersen Fagerlid, Trond Harder Paulsen, Trine Bjøro, Liv Ingrid Flinder

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Tissue Ablation: Applications and Perspectives.Advanced materials (Deerfield Beach, Fla.) · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pål Stefan FrichDivision of Radiology and Nuclear Medicine, Department of Radiology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-8325-7332
Eva SigstadDivision of Laboratory Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway.
Audun Elnæs BerstadDivision of Radiology and Nuclear Medicine, Department of Radiology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-5862-3329
Kristin Holgersen FagerlidDivision of Radiology and Nuclear Medicine, Department of Radiology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-7338-4189
Trond Harder PaulsenDivision of Cancer Medicine, Department of Breast and Endocrine Surgery, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-6115-1206
Trine BjøroDivision of Laboratory Medicine, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-5578-615X
Liv Ingrid FlinderDivision of Radiology and Nuclear Medicine, Department of Radiology, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NO

Funding

Ødegaard and Frimann-Dahls 8225Radium Hospital Foundation 192011
6 · The paper itself

Abstract

contextEthanol ablation (EA) is considered an alternative to surgery for metastatic lymph nodes from papillary thyroid carcinoma (PTC) in selected patients.

objectiveThe aim of this study was to evaluate the long-term efficacy and safety of this treatment. DESIGN AND

settingAdult patients with PTC who had received EA in lymph node metastasis at a tertiary referral center, and were included in a published study from 2011, were invited to participate in this follow-up study.

methodsRadiologic and medical history were reviewed. Ultrasound examination of the neck was performed by radiologists, and clinical examination was performed by an endocrine surgeon. Response was reported according to predefined criteria for satisfactory EA treatment. Adverse events associated with EA were evaluated. Cause of death was reported for deceased patients.

resultsFrom the 2011 study, 51 of 63 patients were included. Forty-four patients were reexamined (67/109 lesions) and 7 patients were deceased. Median follow-up time from primary surgery was 14.5 years. Median follow-up from the latest performed EA in the 2011 study was 11.3 years. Local control was permanently achieved in most patients (80%). Recurrence within an ablated node was registered in 13 metastases in 10 patients. Seven of these patients also had recurrent disease elsewhere in the neck. No major side effects were reported.

conclusionEA is a minimally invasive procedure with a low risk of complications. Our data suggest that EA is a safe and efficient treatment, providing excellent results for a large group of patients in the long term.

Indexed as

Carcinoma, PapillaryThyroid NeoplasmsAdultEthanolFollow-Up StudiesHumansLymph NodesNeoplasm Recurrence, LocalThyroid Cancer, PapillaryThyroidectomyEthanol

Identifiers

PMID34922379
PMCPMC9016442
OpenAlexW4200012925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.